# FDA 483_RESPONSE - Eli Lilly & Company - March 16, 2021

Source: https://www.keypedia.com/records/483_response/eli-lilly-company/48bca0f9-fb52-4f51-9e65-4d0fd6283a21

> FDA 483_RESPONSE for Eli Lilly & Company on March 16, 2021. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483_RESPONSE
- Company Name: Eli Lilly & Company
- Inspection Date: 2021-03-16
- Product Type: Drugs
- Office Name: Division of Pharmaceutical Quality Operations I

## Related Documents

- [483 - 2023-06-16](https://www.keypedia.com/records/483/eli-lilly-company/ad3d5c22-c165-4f63-91cc-163c31217be2)
- [483 - 2023-10-06](https://www.keypedia.com/records/483/eli-lilly-company/f0349542-8a47-4147-9164-7ecacf1fcd4e)
- [483 - 2021-03-16](https://www.keypedia.com/records/483/eli-lilly-company/9fdf10fc-bc85-478c-affd-9279176c5cb7)
- [EIR - 2020-03-20](https://www.keypedia.com/records/eir/eli-lilly-company/9e8da9ed-234b-4013-bd23-c71b99acb878)
- [WARNING_LETTER_RESPONSE - 2001-02-23](https://www.keypedia.com/records/warning_letter_response/eli-lilly-company/e90881d9-e2fa-473e-ab9d-4415ee00f701)

## Related Officers

- [Director of Compliance](https://www.keypedia.com/people/nicholas-f-lyons/e52983af-3992-493c-addd-ff1dfa59eefb)
- [Program Division Director](https://www.keypedia.com/people/art-o-czabaniuk/37f1e249-9ee6-4275-9c28-391d93659b85)
- [Ainhoa Nieto](https://www.keypedia.com/people/ainhoa-nieto/89b22b5d-c0a2-4f0f-9c2c-8244b5cbb793)
- [Ms.](https://www.keypedia.com/people/ann-connery/49b086d7-8b1c-4399-9666-b7d96b340e71)
- [Consumer Safety Officer](https://www.keypedia.com/people/kenneth-o-gee/d61312c0-1422-4487-a5d6-ec6e76d242ee)

Company: https://www.keypedia.com/companies/eli-lilly-company/fc56eed7-d261-4de3-865e-c2aa54162adf

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-i/6ded4818-ee3a-46a1-84c1-36de58502b02